bioAffinity Technologies, Inc. announced on June 3, 2025, its collaboration with Cardinal Health OptiFreight® Logistics. This partnership aims to enhance the national sample delivery capabilities for CyPath® Lung, the company's noninvasive lung cancer diagnostic test.
The collaboration addresses the growing demand for CyPath® Lung by ensuring reliable and efficient transportation of patient samples. This logistical support is crucial for scaling the commercialization of the test across the United States.
By optimizing its supply chain, bioAffinity Technologies can better serve its expanding base of clinicians and patients, reinforcing its commitment to making early lung cancer detection more accessible and efficient within the healthcare system.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.